ArticleFrontiers in cellular and infection microbiology2026
Clinical, microbial and metabolic characteristics of gas-forming pyogenic liver abscess and its potential formation mechanism.
Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- SOFA score in gas-forming pyogenic liver abscess: a case series of seven patients with exploratory analysis of severity and mortality.Frontiers in medicine · 2026Article
- A rare case report of pyogenic hepatic abscess secondary to sigmoid diverticulitis.SAGE open medical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pyogenic liver abscess (PLA) is a common intra-abdominal infection with substantial morbidity and mortality, among which gas-forming pyogenic liver abscess (GFPLA) represents a more severe clinical subtype. Basically, GFPLA is usually associated with more severe clinical outcomes compared to non-gas-forming PLA (non-GFPLA). The underlying mechanisms driving gas formation remain unclear. This study aimed to explore clinical, microbial, and metabolic characteristics of GFPLA. Materials and methods: A total of 176 PLA patients (39 GFPLA, 137 non-GFPLA) were retrospectively analyzed. Clinical variables were compared between groups. Pus samples collected from patients undergoing percutaneous drainage were analyzed using 16S rDNA sequencing and untargeted metabolomics to investigate microbial composition and metabolic differences. Results: GFPLA patients showed worse liver function, higher inflammatory markers, poorer glycemic control, and higher in-hospital mortality. 16S rDNA sequencing revealed no significant differences in bacterial richness, diversity, or community composition between groups, with Conclusion: Diabetes mellitus is an independent risk factor for GFPLA. Gas formation in PLA is more likely linked to high blood glucose-induced metabolic alterations in the liver micro-environment rather than microbial composition. These findings suggest new potential therapeutic targets by modulating metabolic pathways to improve GFPLA outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.